The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Thiazolidinediones
Abstract
Despite a large need for new hypoglycemic therapies, given the epidemic of type 2 diabetes, very few agents have been introduced during the past 20 years. The thiazolidinediones represent a potentially important new group of drugs with a mechanism of action differing from and perhaps complementary to that of existing therapies. This article discusses present data on mechanisms, indications, and limitations of thiazolidinedione therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These actions modulate the transcription of genes with favorable effects on insulin sensitivity,13,36 fat distribution,37 plasma glucose,35,38 lipid and protein metabolism,36,38 vascular endothelial function,39 and inflammation.35,40”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [35]
In the citing paper
“Pioglitazone activates PPAR-γ and also causes partial activation of PPAR-α.35”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [35]
In the citing paper
“Thiazolidinediones (TZDs or glitazones) are peroxisome proliferator–activated receptor γ modulators; they increase the sensitivity of muscle, fat, and liver to endogenous and exogenous insulin (“insulin sensitizers”) (31).”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [31]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1595 · Cited by 3,133
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30
Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., et al. (2002) · Nature Medicine · doi:10.1038/nm724 · Cited by 2,088
Nuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., & Matsubara, K. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0587 · Cited by 2,083
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,659
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Association of Hypoadiponectinemia With Coronary Artery Disease in Men
Kumada, M., Kihara, S., Sumitsuji, S., Kawamoto, T., Matsumoto, S., Ouchi, N., Arita, Y., Okamoto, Y., Shimomura, I., Hiraoka, H., et al. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000048856.22331.50 · Cited by 1,420
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
The prevalence and etiology of elevated aminotransferase levels in the United States
Clark, J. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00265-x · Cited by 1,360
Knochenhauer, E. S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.9.3078 · Cited by 1,127
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1235 · Cited by 995
He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J. M., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536828100 · Cited by 976
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
Nonalcoholic fatty liver disease
Clark, J. M., Brancati, F. L., & Diehl, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.33573 · Cited by 901
Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Role of Adiponectin in Preventing Vascular Stenosis
Matsuda, M., Shimomura, I., Sata, M., Arita, Y., Nishida, M., Maeda, N., Kumada, M., Okamoto, Y., Nagaretani, H., Nishizawa, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206083200 · Cited by 811
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Yu, J. G., Javorschi, S., Hevener, A. L., Kruszynska, Y. T., Norman, R. A., Sinha, M., & Olefsky, J. M. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2968 · Cited by 725
Vozarova, B., Stefan, N., Lindsay, R. S., Saremi, A., Pratley, R. E., Bogardus, C., & Tataranni, P. A. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1889 · Cited by 717
Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
Shyng, S.-L., Lehmann, S., Moulder, K. L., & Harris, D. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.30221 · Cited by 704
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 629
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Combs, T. P., Wagner, J. A., Berger, J., Doebber, T., Wang, W.-J., Zhang, B. B., Tanen, M., Berg, A. H., O’Rahilly, S., Savage, D. B., et al. (2002) · Endocrinology · doi:10.1210/endo.143.3.8662 · Cited by 565
Fonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
Katzenellenbogen, J. A. (1996) · Molecular Endocrinology · doi:10.1210/me.10.2.119 · Cited by 535
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Self-citationRosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Adams, M., Montague, C. T., Prins, J. B., Holder, J. C., Smith, S. A., Sanders, L., Digby, J. E., Sewter, C. P., Lazar, M. A., Chatterjee, V. K., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119870 · Cited by 517
Muscle-specific Pparg deletion causes insulin resistance
Hevener, A. L., He, W., Barak, Y., Le, J., Bandyopadhyay, G., Olson, P., Wilkes, J., Evans, R. M., & Olefsky, J. (2003) · Nature Medicine · doi:10.1038/nm956 · Cited by 492
Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431
Self-citationA futile metabolic cycle activated in adipocytes by antidiabetic agents
Guan, H.-P., Li, Y., Jensen, M. V., Newgard, C. B., Steppan, C. M., & Lazar, M. A. (2002) · Nature Medicine · doi:10.1038/nm780 · Cited by 428
Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects
Suter, S. L., Nolan, J. J., Wallace, P., Gumbiner, B., & Olefsky, J. M. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.193 · Cited by 420
Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Yang, W.-S., Jeng, C.-Y., Wu, T.-J., Tanaka, S., Funahashi, T., Matsuzawa, Y., Wang, J.-P., Chen, C.-L., Tai, T.-Y., & Chuang, L.-M. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.376 · Cited by 405
Lipid overload and overflow: metabolic trauma and the metabolic syndrome
UNGER, R. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2003.09.008 · Cited by 401
Serum Adiponectin and Leptin Levels in Patients with Lipodystrophies
Haque, W. A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.5.2395 · Cited by 395
Azziz, R. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1626 · Cited by 376
Einhorn, D., Rendell, M., Rosenzweig, J., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 368
Initial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359
Bajaj, M., Suraamornkul, S., Piper, P., Hardies, L. J., Glass, L., Cersosimo, E., Pratipanawatr, T., Miyazaki, Y., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031315 · Cited by 358
Raskin, P., Rendell, M., Riddle, M. C., Dole, J. F., Freed, M. I., Rosenstock, J., & For the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1226 · Cited by 345
Berger, J. P., Petro, A. E., Macnaul, K. L., Kelly, L. J., Zhang, B. B., Richards, K., Elbrecht, A., Johnson, B. A., Zhou, G., Doebber, T. W., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0217 · Cited by 321
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319
Self-citationActivation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3868 · Cited by 313
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303
Henke, B. R., Blanchard, S. G., Brackeen, M. F., Brown, K. K., Cobb, J. E., Collins, J. L., Harrington, Hashim, M. A., Hull-Ryde, E. A., Kaldor, I., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9804127 · Cited by 301
Combination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
Self-citationBajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290
Lessons from the glitazones: a story of drug development
Gale, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04960-6 · Cited by 287
TNF-α and insulin resistance: Summary and future prospects
Peraldi, P., & Spiegelman, B. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006865715292 · Cited by 286
Kipnes, M. S., Krosnick, A., Rendell, M. S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00713-6 · Cited by 281
Miyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetologia · doi:10.1007/s001250100031 · Cited by 274
A Diabetes Outcome Progression Trial (ADOPT)
Viberti, G., Kahn, S. E., Greene, D. A., Herman, W. H., Zinman, B., Holman, R. R., Haffner, S. M., Levy, D., Lachin, J. M., Berry, R. A., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1737 · Cited by 273
INSULIN ACTION IN THE NORMAL AND POLYCYSTIC OVARY
Franks, S., Gilling-Smith, C., Watson, H., & Willis, D. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70074-8 · Cited by 263
Marx, N., Froehlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Scharnagl, H., Hombach, V., & Koenig, W. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054195.35121.5e · Cited by 257
Khan, M. A., St. Peter, J. V., & Xue, J. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.708 · Cited by 250
Sidhu, J. S., Kaposzta, Z., Markus, H. S., & Kaski, J. C. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000124890.40436.77 · Cited by 248
Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes
Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.517 · Cited by 236
Hirose, H., Kawai, T., Yamamoto, Y., Taniyama, M., Tomita, M., Matsubara, K., Okazaki, Y., Ishii, T., Oguma, Y., Takei, I., et al. (2002) · Metabolism · doi:10.1053/meta.2002.30506 · Cited by 235
Pathogenesis of non-insulin-dependent diabetes mellitus
Yki-Järvinen, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90821-4 · Cited by 227
Self-citationTHE EPIDEMIOLOGY OF POLYCYSTIC OVARY SYNDROME
Solomon, C. G. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70069-4 · Cited by 226
Modulation of Circulating and Adipose Tissue Adiponectin Levels by Antidiabetic Therapy
Phillips, S. A., Ciaraldi, T. P., Kong, A. P. S., Bandukwala, R., Aroda, V., Carter, L., Baxi, S., Mudaliar, S. R., & Henry, R. R. (2003) · Diabetes · doi:10.2337/diabetes.52.3.667 · Cited by 226
Rosenblatt, S., Miskin, B., Glazer, N. B., Prince, M. J., & Robertson, K. E. (2001) · Coronary Artery Disease · doi:10.1097/00019501-200108000-00011 · Cited by 221
Addy, C. L., Gavrila, A., Tsiodras, S., Brodovicz, K., Karchmer, A. W., & Mantzoros, C. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020795 · Cited by 220
Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials
Lebovitz, H. E., Kreider, M., & Freed, M. I. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.815 · Cited by 218
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Carey, D. G., Cowin, G. J., Galloway, G. J., Jones, N. P., Richards, J. C., Biswas, N., & Doddrell, D. M. (2002) · Obesity Research · doi:10.1038/oby.2002.137 · Cited by 210
Berger, J., Tanen, M., Elbrecht, A., Hermanowski-Vosatka, A., Moller, D. E., Wright, S. D., & Thieringer, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m003592200 · Cited by 208
Rosenstock, J., Einhorn, D., Hershon, K., Glazer, N., & Yu, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11251.x · Cited by 193
Reitman, M. L., Arioglu, E., Gavrilova, O., & Taylor, S. I. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00309-x · Cited by 193
Dubois, M., Pattou, F., Kerr-Conte, J., Gmyr, V., Vandewalle, B., Desreumaux, P., Auwerx, J., Schoonjans, K., & Lefebvre, J. (2000) · Diabetologia · doi:10.1007/s001250051508 · Cited by 189
Sutinen, J., Häkkinen, A.-M., Westerbacka, J., Seppälä-Lindroos, A., Vehkavaara, S., Halavaara, J., Järvinen, A., Ristola, M., & Yki-Järvinen, H. (2003) · Antiviral Therapy · doi:10.1177/135965350300800303 · Cited by 189
Self-citationDuez, H., Chao, Y.-S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C. A., Tedgui, A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206966200 · Cited by 186
Ghazeeri, G., Kutteh, W. H., Bryer-Ash, M., Haas, D., & Ke, R. W. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04843-4 · Cited by 182
Tack, C. J. J., Ong, M. K. E., Lutterman, J. A., & Smits, P. (1998) · Diabetologia · doi:10.1007/s001250050948 · Cited by 177
Caballero, A. E., Saouaf, R., Lim, S. C., Hamdy, O., Abou-Elenin, K., O'Connor, C., LoGerfo, F. W., Horton, E. S., & Veves, A. (2003) · Metabolism · doi:10.1053/meta.2003.50023 · Cited by 170
Seppala-Lindroos, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3023 · Cited by 168
Self-citationRieusset, J., Auwerx, J. H., & Vidal, H. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1657 · Cited by 143
Smith, U., Gogg, S., JOHANSSON, A., Olausson, T., Sopasakis, V. R., & SVALSTEDT, B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0020com · Cited by 131
Combs, T. P. (2002) · Endocrinology · doi:10.1210/en.143.3.998 · Cited by 126
Ljung, B., Bamberg, K., Dahllöf, B., Kjellstedt, A., Oakes, N. D., Östling, J., Svensson, L., & Camejo, G. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200127-jlr200 · Cited by 115
Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
Gomez-Perez, F. J., Fanghänel‐Salmón, G., Barbosa, J. A., Montes‐Villarreal, J., Berry, R. A., Warsi, G. M., & Gould, E. M. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.264 · Cited by 113
Mynarcik, D. C., Combs, T. P., McNurlan, M. A., Scherer, P. E., Komaroff, E., & Gelato, M. C. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200212150-00009 · Cited by 113
Sutinen, J., Korsheninnikova, E., Funahashi, T., Matsuzawa, Y., Nyman, T., & Yki‐Järvinen, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021922 · Cited by 93
Self-citationScherbaum, W. A., Göke, B., & and the German Pioglitazone Study Group (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-35421 · Cited by 80
Insulin-Lowering Drugs In Polycystic Ovary Syndrome
Iuorno, M. J., & Nestler, J. E. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70191-1 · Cited by 79
Michalik, L., Desvergne, B., & Wahli, W. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200304000-00003 · Cited by 75
Yki‐Järvinen, H., Sutinen, J., Silveira, A. M. V., Korsheninnikova, E., Fisher, R. M., Kannisto, K., Ehrenborg, E., Eriksson, P. O., & Hamsten, A. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000062885.61917.a5 · Cited by 71
Self-citationCzoski‐Murray, C., Warren, E., Chilcott, J. B., Beverley, C., Psyllaki, M., & Cowan, J. (2004) · Health Technology Assessment · doi:10.3310/hta8130 · Cited by 50
Vongthavaravat, V., WAJCHENBERG, B. L., Waitman, J. N., Añel-Quimpo, J., Menon, P. S. N., Khalifa, F. B., & Chow, W.-H. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001236 · Cited by 40
How will we know if 11β‐hydroxysteroid dehydrogenases are important in common diseases*
Walker, B. R. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00969.x · Cited by 15
Research works printed but not linked: 3
- Yki-Järvinen H. Insulin resistance in type 2 diabetes. In: Pickup JC, Williams G, eds. Textbook of diabetes. 3rd ed. Oxford, England: Blackwell, 2003:22.1-22.19.
- 10.1111/j.1572-0241.2003.07486.x · doi:10.1111/j.1572-0241.2003.07486.x · Paper page
- Charbonnel B, 2002, Diabetologia, 45, A107
Cited by
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Metadata
- Authors
- Yki-Järvinen, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-09-09
- Volume
- 351
- Issue
- 11
- Pages
- 1106-1118
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4240449862
- Cited by
- 1,830
- References
- 110
- Citations by year
- 2026: 26 · 2025: 33 · 2024: 41 · 2023: 45 · 2022: 57 · 2021: 60 · 2020: 55 · 2019: 53 · 2018: 74 · 2017: 74 · 2016: 65 · 2015: 76 · 2014: 75 · 2013: 94 · 2012: 108
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- thiazolidinediones, type 2 diabetes, hypoglycemic therapy, mechanism of action, antidiabetic drugs, drug indications, drug limitations
- MeSH terms
- Adipose Tissue, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fatty Liver, Female, Gene Expression Regulation, Humans, Hypoglycemic Agents, Insulin Resistance, Lipodystrophy, Polycystic Ovary Syndrome, Risk Factors, Transcription Factors, Biomarkers, Receptors, Cytoplasmic and Nuclear, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.